Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Cancer Immunology, Immunotherapy

Volumn 64, Issue 1, 2015, Pages 61-73

  Balasa, Balaji ^a,d   Yun, Rui ^b   Belmar, Nicole A ^b   Fox, Melvin ^b   Chao, Debra T ^b   Robbins, Michael D ^c   Starling, Gary C ^a,e   Rice, Audie G ^b,c  

^a Abbott Biotherapeutics Corp   (United States)

^b ABBVIE INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d AGILENT TECHNOLOGIES   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Elotuzumab; Interleukin 2; Lenalidomide; Multiple myeloma; Natural killer cell activation; SLAMF7

Indexed keywords

CYTOKINE; ELOTUZUMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DEATH; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935042811     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1610-3     Document Type: Article

References (40)

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060
2. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 154:745–754
3. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445–4451
4. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinosa L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10:155–167
5. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56–63
6. De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A et al (2011) Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 17:1935–1946
7. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DC, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78–86
8. + tumor cells. Clin Cancer Res 14:4650–4657
9. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925–1932
10. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R et al (2005) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 65:11712–11720
11. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216
12. Shannon E, Sandoval F, Greig N, Stagg P (2012) Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro… a possible explanation for their mechanism of action in treating multiple myeloma. Int Immunopharmacol 12:441–446
13. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840–1848
14. Lutz RJ, Whiteman KR (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 1:548–551
15. Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shrinqarpure R, Shi J et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688–3696
16. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180:699–705
17. Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nquyen DH, Karki S, Chu SY, Lazar GA et al (2012) Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119:2074–2082
18. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S (2009) An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 84:650–656
19. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13:6469–6478
20. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O’Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR (2011) Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol 154:533–535
21. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG et al (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775–2784
22. Veillette A, Guo H (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88:168–177
23. ClinicalTrials.gov. Biomarker study of elotuzumab in high risk smoldering myeloma. http://www.clinicaltrials.gov/ct2/show/NCT01441973
24. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329–1337
25. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B et al (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 8:2616–2624
26. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr (2013) Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62:1841–1849
27. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552–559
28. Richardson PG, Jagannath S, Moreau P, Jakubowiak A, Raab MS, Facon T, et al. A phase 2 study of elotuzumab (Elo) combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results. Presented at: 54th American Society of Hematology annual meeting and exposition; Atlanta, GA, USA; December 8–11, 2012. Abstract 202
29. Cole MS, Anasetti C, Tso JY (1997) Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 159:3613–3621
30. Barber DF, Faure M, Long EO (2004) LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 173:3653–3659
31. Gross CC, Brzostowski JA, Liu D, Long EO (2010) Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization. J Immunol 185:2918–2926
32. Hildreth JE, Gotch FM, Hildreth PD, McMichael AJ (1983) A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur J Immunol 13:202–208
33. Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A (2009) Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol 10:973–980
34. Yoon WS, Chae YS, Hong J, Park YK (2011) Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice. Appl Microbiol Biotechnol 89:1807–1819
35. Nagasaki E, Takahara A, Koido S, Sagawa S, Aiba K, Tajiri H, Yagita H, Homma S (2010) Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway. J Immunother 33:467–474
36. Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S et al (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:3227–3237
37. Huang MC, Greig NH, Luo W, Tweedie D, Schwartz JB, Longo DL, Ferrucci L, Ershler WB, Goetzl EJ (2011) Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. Clin Immunol 138:201–211
38. Caron PC, Lai LT, Scheinberg DA (1995) Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1:63–70
39. Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, Tatematsu M (2008) Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci 99:1471–1478
40. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M (2003) Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88:1002–1012